Raymond James & Associates Purchases 1,875 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Raymond James & Associates raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 15.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,286 shares of the biopharmaceutical company’s stock after purchasing an additional 1,875 shares during the quarter. Raymond James & Associates’ holdings in Alnylam Pharmaceuticals were worth $2,734,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Raymond James Financial Services Advisors Inc. grew its stake in shares of Alnylam Pharmaceuticals by 9.4% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 11,850 shares of the biopharmaceutical company’s stock worth $1,935,000 after acquiring an additional 1,017 shares during the period. MetLife Investment Management LLC purchased a new position in shares of Alnylam Pharmaceuticals in the first quarter worth approximately $1,268,000. Panagora Asset Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 96.4% in the first quarter. Panagora Asset Management Inc. now owns 6,565 shares of the biopharmaceutical company’s stock worth $1,072,000 after buying an additional 3,223 shares during the last quarter. Great West Life Assurance Co. Can boosted its holdings in shares of Alnylam Pharmaceuticals by 21.2% in the first quarter. Great West Life Assurance Co. Can now owns 62,369 shares of the biopharmaceutical company’s stock worth $10,786,000 after buying an additional 10,892 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Alnylam Pharmaceuticals by 1.2% in the first quarter. Dimensional Fund Advisors LP now owns 181,271 shares of the biopharmaceutical company’s stock worth $29,601,000 after buying an additional 2,111 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Chardan Capital dropped their price objective on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating on the stock in a report on Friday, February 16th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $165.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. JPMorgan Chase & Co. lifted their price target on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a report on Thursday, February 1st. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Finally, Wells Fargo & Company lowered their price target on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a report on Friday, February 16th. Eight research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $216.12.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $148.50 on Monday. The company’s fifty day moving average is $153.99 and its 200 day moving average is $167.73. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $143.52 and a fifty-two week high of $218.88. The stock has a market capitalization of $18.70 billion, a PE ratio of -41.71 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. During the same quarter in the prior year, the firm posted ($1.68) EPS. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -4.54 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.